Hassel Jessica C, Zimmer Lisa
Medizinische Fakultät, Hautklinik und Nationales Centrum für Tumorerkrankungen (NCT), NCT Heidelberg, eine Partnerschaft zwischen DKFZ und dem Universitätsklinikum Heidelberg, Universität Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland.
Klinik für Dermatologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Deutschland.
Dermatologie (Heidelb). 2024 Jun;75(6):466-475. doi: 10.1007/s00105-024-05354-3. Epub 2024 May 27.
Immune checkpoint inhibitors (ICIs) such as PD(L)1 and CTLA4 antibodies as well as targeted therapies such as BRAF and MEK inhibitors have significantly improved the systemic treatment of skin cancer in adjuvant and advanced therapy settings. All these drugs differ in their spectrum of side effects.
The aim of this article is to provide an overview of the spectrum of side effects of dermato-oncological therapies and their management, taking into account the current literature.
The most important side effects of ICIs, the CCR4 inhibitor mogamulizumab, the ImmTAC tebentafusp, the BRAF and MEK inhibitors and the multityrosine kinase inhibitor imatinib are considered.
Side effects can manifest themselves in all organ systems. Chronic side effects and long-term harm are possible, especially with ICIs, and require close therapy monitoring and patient education. Knowledge of the side effects and the temporal, sometimes delayed course of their occurrence are essential for diagnosis and prompt initiation of therapy.
免疫检查点抑制剂（ICIs），如PD(L)1和CTLA4抗体，以及靶向治疗药物，如BRAF和MEK抑制剂，在辅助治疗和晚期治疗中显著改善了皮肤癌的全身治疗。所有这些药物的副作用谱各不相同。
本文旨在结合当前文献，概述皮肤肿瘤学治疗的副作用谱及其管理。
考虑了ICIs、CCR4抑制剂莫格利珠单抗、免疫衔接器替贝福司、BRAF和MEK抑制剂以及多酪氨酸激酶抑制剂伊马替尼的最重要副作用。
副作用可在所有器官系统中表现出来。慢性副作用和长期损害是可能的，尤其是使用ICIs时，需要密切的治疗监测和患者教育。了解副作用及其发生的时间，有时是延迟发生的过程，对于诊断和及时开始治疗至关重要。
Zotero 插件